SciSparc Ltd.
No SEC Form 4 filings for $SPRC in the last 30 days.
See all $SPRC insider activity →SciSparc (SPRC) and Clearmind (CMND) advanced their MDMA-PEA patent for PTSD treatment. The U.S. FDA issued psychedelic drug guidance, aiding their development. SPRC and CMND traded at $6.70 and $1.74 respectively, with slight premarket declines.
SciSparc (NASDAQ:SPRC) shares fell 20.31% to $6.93 in premarket trading, as broader markets were slightly higher. The company said its subsidiary NeuroThera Labs completed internal validation of a quantum sampling workflow for clinical analytics and began a Phase IIb trial site at Hannover Medical School for SCI-110, a cannabinoid treatment for adult Tourette syndrome.
Biotech gainers included SciSparc (SPRC) after its subsidiary NeuroThera Labs completed internal validation of a quantum sampling platform. Avantor (AVTR) rose after Q2 results and raised 2026 adjusted EPS to $0.80-$0.83. NeoGenomics (NEO) lifted 2026 revenue guidance to $802-$806M. Other movers: Alvotech (ALVO) on FDA facility inspection, Sanara MedTech (SMTI) to be acquired by MiMedx (MDXG), and LB Pharmaceuticals (LBRX) after a ~$150M private placement.
Over the past 7 days, alphai's AI scored 1 news story mentioning SPRC (SciSparc Ltd.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent SPRC coverage spans technology, market movers and mergers & acquisitions.
Potential therapeutic advantage could boost pipeline value and attract partnership interest.
The disclosed clinical and analytics progress is positive in principle, but the stock is trading sharply lower, implying investors are reacting to other near-term concerns not detailed here.
Quantum analytics validation is a positive technical milestone, but it is internal validation rather than regulatory or clinical readout.
Validation is a technical milestone that could support longer-term platform development, but it does not disclose clinical, regulatory, or commercial outcomes.
The disclosure is a strategic pivot toward agentic AI and cybersecurity, but it provides no quantified financial commitments or near-term milestones.
alphai scores every news story that mentions SPRC with an AI model for sentiment and relevance, and aggregates insider trades from SciSparc Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
SciSparc (SPRC) and Clearmind (CMND) advanced their MDMA-PEA patent for PTSD treatment. The U.S. FDA issued psychedelic drug guidance, aiding their development. SPRC and CMND traded at $6.70 and $1.74 respectively, with slight premarket declines.
2 min readSciSparc (NASDAQ:SPRC) shares fell 20.31% to $6.93 in premarket trading, as broader markets were slightly higher. The company said its subsidiary NeuroThera Labs completed internal validation of a quantum sampling workflow for clinical analytics and began a Phase IIb trial site at Hannover Medical School for SCI-110, a cannabinoid treatment for adult Tourette syndrome.
3 min readBiotech gainers included SciSparc (SPRC) after its subsidiary NeuroThera Labs completed internal validation of a quantum sampling platform. Avantor (AVTR) rose after Q2 results and raised 2026 adjusted EPS to $0.80-$0.83. NeoGenomics (NEO) lifted 2026 revenue guidance to $802-$806M. Other movers: Alvotech (ALVO) on FDA facility inspection, Sanara MedTech (SMTI) to be acquired by MiMedx (MDXG), and LB Pharmaceuticals (LBRX) after a ~$150M private placement.
3 min readSciSparc Ltd. (Nasdaq: SPRC) said its subsidiary NeuroThera Labs (TSXV: NTLX) completed internal validation of a proprietary quantum sampling workflow for clinical-trial data analytics. The workflow represents continuous probability distributions in a hybrid quantum-classical framework using QMCMC, implemented on an S&P 500 company platform. NeuroThera holds 54.01% of CliniQuantum.
4 min readSciSparc Ltd. (Nasdaq: SPRC) said its board decided to target the agentic AI market and will form a Scientific Advisory Board focused on AI and cybersecurity. The company said it is evaluating opportunities and discussing with several agentic AI companies. SciSparc also noted its clinical-stage cannabinoid drug programs via NeuroThera.
2 min readBiotech gainers highlighted include Advanced Biomed (ADVB), up about 211% this week to $16.78, with no product sales and a recent SEC registration withdrawal. Novocure (NVCR) rose over 28% after Q2 results and raised 2026 revenue guidance to $710M-$725M. Medpace (MEDP) gained 14% on Q2 revenue of $707.3M and 2026 outlook. SciSparc (SPRC) and Agenus (AGEN) also rose; AgomAb (AGMB) gained on upcoming trial readouts.
7 min readSciSparc Ltd. (SPRC) said its subsidiary NeuroThera Labs (NTLX.V) started a Phase IIb site for SCI-110, an investigational oral treatment for adult Tourette syndrome. The randomized, double-blind, placebo-controlled cross-over trial will assess tic severity via the Yale Global Tic Severity Scale at weeks 12 and 26. Company cites Phase IIa average tic reduction of 21%.
4 min readSciSparc Ltd. (Nasdaq: SPRC) said its subsidiary NeuroThera Labs (TSXV: NTLX) started a Phase IIb clinical trial site at Hannover Medical School in Germany for SCI-110, a cannabinoid-based treatment for adult Tourette syndrome. The randomized, double-blind, placebo-controlled cross-over study follows Phase IIa results showing 21% average tic reduction.
4 min readSciSparc Ltd. shares (SPRC) rose about 34% in Thursday trading after its subsidiary NeuroThera Labs completed the acquisition of roughly 54% of CliniQuantum Ltd., according to the company. NeuroThera paid with common shares valued at about C$9.5 million. On Nasdaq, SPRC was around $12.68, up 34.63%, after opening at $13.52.
2 min readSciSparc Ltd. shares (SPRC) rose about 34% in Thursday trading after its subsidiary, NeuroThera Labs Inc., completed the acquisition of roughly 54% of CliniQuantum Ltd., according to the company. The deal was made in common shares valued at about C$9.5 million. On Nasdaq, SPRC was at $12.68, up 34.63%, after opening at $13.52.
2 min read
